Medication info
Rosuvastatin Calcium Tablets 5 mg (Undifferentiated)

Rosuvastatin Calcium Tablets 5 mg (Undifferentiated)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium Micronized›5.2mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Yellow round film-coated tablets
Packaging
30 tablets (10 tablets/PTP × 3)
Approval status
Active

MFDS item code 201400451 · Approved 2014.01.29 · Insurance code 657202670

Summary

Main use
Improvement of dyslipidemia; inhibition of atherosclerosis progression; prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased up to a maximum of 20 milligrams daily. 3. Elderly patients: No dosage adjustment is required. 4. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Child dose
Ages 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or more. Under 10 years: Safety and efficacy have not been established.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia; inhibition of atherosclerosis progression; prevention of cardiovascular disease

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • atherosclerosis
  • dysbetalipoproteinemia
  • coronary heart disease
  • stroke
  • myocardial infarction
  • arterial revascularization
View approved original text

This medication is primarily used as an adjunct in patients with hypercholesterolemia and mixed dyslipidemia who cannot be adequately controlled with diet and exercise. It is also used in patients with homozygous familial hypercholesterolemia in conjunction with diet or other lipid-lowering therapies to reduce total cholesterol and LDL-cholesterol, thus delaying the progression of atherosclerosis. In pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia and cholesterol levels exceeding certain criteria, it is used as an adjunct to diet. Additionally, it aids patients with primary dysbetalipoproteinemia and contributes to reducing the risk of myocardial infarction, stroke, and arterial revascularization in elderly men and women with elevated high-sensitivity C-reactive protein and additional cardiovascular risk factors. This medication is effectively used for managing cholesterol and reducing cardiovascular disease risk.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased up to a maximum of 20 milligrams daily. 3. Elderly patients: No dosage adjustment is required. 4. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Child dose

Ages 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or more. Under 10 years: Safety and efficacy have not been established.

Precautions

This medication should not be used in specific patients. For example, it should not be administered to patients with allergies to any component of this medication, severe liver impairment, muscle disorders, patients taking certain immunosuppressants, patients with severely impaired kidney function, or women who are pregnant or breastfeeding. Moreover, high-dose administration is prohibited in patients at increased risk of muscle disorders. This medication contains lactose, so patients with lactose intolerance should not take it. This medication can affect liver function and muscles, therefore patients who consume a lot of alcohol or who have a history of liver disease should be cautious. It is recommended to repeatedly check liver enzymes before and during administration to monitor liver status. Symptoms such as muscle pain, weakness, or cramps should be reported to healthcare providers immediately, and if necessary, the medication should be discontinued. Patients at risk of serious muscle damage, such as those with kidney impairment, hypothyroidism, a history of muscle disorders, the elderly, or those who abuse alcohol should be closely monitored for muscle status before and after treatment. This medication can rarely cause serious skin reactions or liver damage; therefore, if symptoms like skin rashes or jaundice occur, the medication should be stopped immediately and a physician consulted. This medication can interact with other drugs, so if other medications are being taken, it is essential to inform the doctor or pharmacist. In particular, concomitant use with some antiviral agents, immunosuppressants, certain antibiotics, and fibrate-class medications may increase the risk of muscle damage. Women who are pregnant or planning to become pregnant should not take this medication and should use appropriate contraception. Similarly, its use is not recommended during breastfeeding. In the case of overdose, there are no specific antidotes, so treatment should be symptom-based, and liver function and muscle enzyme levels should be monitored periodically. This medication does not significantly affect the ability to drive or operate machinery; however, caution should be exercised as dizziness may occur rarely. Finally, this medication may present higher serum concentrations in Asians, necessitating potential dosage adjustments.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ophthalmoplegia, thrombocytopenia, jaundice, hepatitis, elevated transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), drug-induced morbilliform eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal hepatic failure, cognitive impairment, elevated ALT, chest pain, muscle cramps, gout, erectile dysfunction, elevated AST, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering. It is recommended to maintain a storage temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow round film-coated tablets

Package unit

30 tablets (10 tablets/PTP × 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.